2.2 Pharmacokinetic Schedule
Iberdomide PK data was collected for all three studies. All available PK data from CP-001, Part 1(multiple ascending dose; Table 1) and 3 (relative bioavailability; Table 1) from CP-002 and cohorts A (iberdomide monotherapy dose escalation; Table 1), B (iberdomide in combination with DEX dose escalation; Table 1), D (iberdomide in combination with DEX dose expansion; Table 1), E (iberdomide in combination with DARA and DEX dose escalation; Table 1),) and I (iberdomide in combination with DEX dose expansion; Table 1) from MM-001 studies were included in the popPK analysis, based upon the relevance to this analysis. M12 PK data was only collected in CC-220-MM-001 Cohorts A, B and E. The sampling schedule of M12 is similar as iberdomide.
The PK sampling schedule was detailed in Table 1.